Format
Sort by

Send to

Choose Destination

Links from Protein

Items: 1 to 20 of 96

1.

Overexpression of Rad51C splice variants in colorectal tumors.

Kalvala A, Gao L, Aguila B, Reese T, Otterson GA, Villalona-Calero MA, Duan W.

Oncotarget. 2015 Apr 20;6(11):8777-87.

2.

Single nucleotide polymorphisms in noncoding regions of Rad51C do not change the risk of unselected breast cancer but they modulate the level of oxidative stress and the DNA damage characteristics: a case-control study.

Gresner P, Gromadzinska J, Jablonska E, Stepnik M, Zambrano Quispe O, Twardowska E, Wasowicz W.

PLoS One. 2014 Oct 24;9(10):e110696. doi: 10.1371/journal.pone.0110696. eCollection 2014.

3.

Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.

Somyajit K, Mishra A, Jameei A, Nagaraju G.

Carcinogenesis. 2015 Jan;36(1):13-24. doi: 10.1093/carcin/bgu211. Epub 2014 Oct 7.

4.

RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.

Blanco A, Gutiérrez-Enríquez S, Santamariña M, Montalban G, Bonache S, Balmaña J, Carracedo A, Diez O, Vega A.

Breast Cancer Res Treat. 2014 Aug;147(1):133-43. doi: 10.1007/s10549-014-3078-4. Epub 2014 Aug 3.

PMID:
25086635
5.

Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.

Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U.

Breast Cancer Res Treat. 2014 Jun;145(3):775-84. doi: 10.1007/s10549-014-2972-0. Epub 2014 May 7.

PMID:
24800917
6.

Utilization of Rad51C promoter for transcriptional targeting of cancer cells.

Cao Y, Xu Y, Zhang L, Li Z, Jiang Y, Tian X, Seluanov A, Gorbunova V, Mao Z.

Oncotarget. 2014 Apr 15;5(7):1805-11.

7.

Rad51C: a novel suppressor gene modulates the risk of head and neck cancer.

Gresner P, Gromadzinska J, Twardowska E, Rydzynski K, Wasowicz W.

Mutat Res. 2014 Apr;762:47-54. doi: 10.1016/j.mrfmmm.2014.02.007. Epub 2014 Mar 12.

PMID:
24631219
8.

RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC).

Scheckenbach K, Baldus SE, Balz V, Freund M, Pakropa P, Sproll C, Schäfer KL, Wagenmann M, Schipper J, Hanenberg H.

Oral Oncol. 2014 Mar;50(3):196-9. doi: 10.1016/j.oraloncology.2013.11.007. Epub 2013 Dec 6.

9.

RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib.

Min A, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, Kim HP, Lee KH, Han SW, Oh DY, Kim TY, O'Connor MJ, Kim WH, Bang YJ.

Mol Cancer Ther. 2013 Jun;12(6):865-77. doi: 10.1158/1535-7163.MCT-12-0950. Epub 2013 Mar 19.

10.

Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.

Pelttari LM, Nurminen R, Gylfe A, Aaltonen LA, Schleutker J, Nevanlinna H.

BMC Cancer. 2012 Nov 23;12:552. doi: 10.1186/1471-2407-12-552.

11.

Germline mutations in RAD51C in Jewish high cancer risk families.

Kushnir A, Laitman Y, Shimon SP, Berger R, Friedman E.

Breast Cancer Res Treat. 2012 Dec;136(3):869-74. doi: 10.1007/s10549-012-2317-9. Epub 2012 Nov 2.

PMID:
23117857
12.

Germline RAD51C mutations in ovarian cancer susceptibility.

Coulet F, Fajac A, Colas C, Eyries M, Dion-Minière A, Rouzier R, Uzan S, Lefranc JP, Carbonnel M, Cornelis F, Cortez A, Soubrier F.

Clin Genet. 2013 Apr;83(4):332-6. doi: 10.1111/j.1399-0004.2012.01917.x. Epub 2012 Jul 23.

PMID:
22725699
13.

Germline RAD51C mutations confer susceptibility to ovarian cancer.

Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D, Warren-Perry M, Snape K; Breast Cancer Susceptibility Collaboration (UK), Eccles D, Evans DG, Gore M, Renwick A, Seal S, Antoniou AC, Rahman N.

Nat Genet. 2012 Apr 26;44(5):475-6; author reply 476. doi: 10.1038/ng.2224. No abstract available.

PMID:
22538716
14.

Mutation screening of RAD51C in high-risk breast and ovarian cancer families.

Lu W, Wang X, Lin H, Lindor NM, Couch FJ.

Fam Cancer. 2012 Sep;11(3):381-5. doi: 10.1007/s10689-012-9523-9.

15.

Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families.

Osorio A, Endt D, Fernández F, Eirich K, de la Hoya M, Schmutzler R, Caldés T, Meindl A, Schindler D, Benitez J.

Hum Mol Genet. 2012 Jul 1;21(13):2889-98. doi: 10.1093/hmg/dds115. Epub 2012 Mar 26.

16.

Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.

De Leeneer K, Van Bockstal M, De Brouwer S, Swietek N, Schietecatte P, Sabbaghian N, Van den Ende J, Willocx S, Storm K, Blaumeiser B, Van Asperen CJ, Wijnen JT, Leunen K, Legius E, Michils G, Matthijs G, Blok MJ, Gomez-Garcia E, De Paepe A, Tischkowitz M, Poppe B, Claes K.

Breast Cancer Res Treat. 2012 May;133(1):393-8. doi: 10.1007/s10549-012-1998-4. Epub 2012 Feb 28.

PMID:
22370629
17.

Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility.

Somyajit K, Subramanya S, Nagaraju G.

J Biol Chem. 2012 Jan 27;287(5):3366-80. doi: 10.1074/jbc.M111.311241. Epub 2011 Dec 13.

18.

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.

Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, kConFab, Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA, Campbell IG.

Hum Mutat. 2012 Jan;33(1):95-9. doi: 10.1002/humu.21625. Epub 2011 Nov 4.

PMID:
21990120
19.

RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.

Clague J, Wilhoite G, Adamson A, Bailis A, Weitzel JN, Neuhausen SL.

PLoS One. 2011;6(9):e25632. doi: 10.1371/journal.pone.0025632. Epub 2011 Sep 28.

20.

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.

Vuorela M, Pylkäs K, Hartikainen JM, Sundfeldt K, Lindblom A, von Wachenfeldt Wäppling A, Haanpää M, Puistola U, Rosengren A, Anttila M, Kosma VM, Mannermaa A, Winqvist R.

Breast Cancer Res Treat. 2011 Dec;130(3):1003-10. doi: 10.1007/s10549-011-1677-x. Epub 2011 Jul 13.

PMID:
21750962
Items per page

Supplemental Content

Write to the Help Desk